Literature DB >> 14510962

Cytogenetic abnormalities in paroxysmal nocturnal haemoglobinuria usually occur in haematopoietic cells that are glycosylphosphatidylinositol-anchored protein (GPI-AP) positive.

Elaine M Sloand1, Monika Fuhrer, Keyvan Keyvanfar, Lori Mainwaring, Jaroslaw Maciejewski, Yu Wang, Sarah Johnson, A John Barrett, Neal S Young.   

Abstract

Some patients with paroxysmal nocturnal haemoglobinuria (PNH) have bone marrow findings characteristic of myelodysplastic syndrome. We studied nine PNH patients to determine whether these karyotypic abnormalities were more likely to occur in glycosylphosphatidylinositol-anchored protein (GPI-AP)-negative cells. Abnormal chromosome patterns were evident only in the GPI-AP-positive populations of the PNH clone in 8 of 9 cases studied. Purified GPI-AP-negative CD34 cells gave rise only to cells of normal karyotype, whereas the progeny of the GPI-AP-positive CD34 cells showed the karyotypic abnormality. These findings suggest that environmental factors, but not genetic instability of the GPI-AP-deficient clone, foster development or survival of haematopoietic cells with chromosomal abnormalities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14510962     DOI: 10.1046/j.1365-2141.2003.04562.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

Authors:  Charles Parker; Mitsuhiro Omine; Stephen Richards; Jun-Ichi Nishimura; Monica Bessler; Russell Ware; Peter Hillmen; Lucio Luzzatto; Neal Young; Taroh Kinoshita; Wendell Rosse; Gerard Socié
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

2.  T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

Authors:  Elaine M Sloand; J Joseph Melenhorst; Zachary C G Tucker; Loretta Pfannes; Jason M Brenchley; Agnes Yong; Valeria Visconte; Colin Wu; Emma Gostick; Phillip Scheinberg; Matthew J Olnes; Daniel C Douek; David A Price; A John Barrett; Neal S Young
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

3.  Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure.

Authors:  Neal S Young
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

4.  Clonality in context: hematopoietic clones in their marrow environment.

Authors:  James N Cooper; Neal S Young
Journal:  Blood       Date:  2017-10-18       Impact factor: 22.113

5.  Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Authors:  Lova Sun; Daria V Babushok
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

6.  Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.

Authors:  Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Loretta Pfannes; Kelsey Loeliger; Zachary Tucker; Xin Tian; Minjung Kwak; Francois Wilhelm; Agnes S M Yong; Irina Maric; Manoj Maniar; Phillip Scheinberg; Jerome Groopman; Neal S Young; Elaine M Sloand
Journal:  Leuk Res       Date:  2012-04-21       Impact factor: 3.156

7.  Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation.

Authors:  Britta Höchsmann; Yoshiko Murakami; Makiko Osato; Alexej Knaus; Michi Kawamoto; Norimitsu Inoue; Tetsuya Hirata; Shogo Murata; Markus Anliker; Thomas Eggermann; Marten Jäger; Ricarda Floettmann; Alexander Höllein; Sho Murase; Yasutaka Ueda; Jun-Ichi Nishimura; Yuzuru Kanakura; Nobuo Kohara; Hubert Schrezenmeier; Peter M Krawitz; Taroh Kinoshita
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

8.  CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins.

Authors:  Elaine M Sloand; Loretta Pfannes; Gubin Chen; Simant Shah; Elena E Solomou; John Barrett; Neal S Young
Journal:  Blood       Date:  2006-11-07       Impact factor: 22.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.